Preparation method of fenerenone crystal form I
By using a high boiling point solvent such as isopropanol for crystallization in the preparation of nonelectroleone, the problems of low yield and high cost in the prior art are solved, and the high yield and good yield of nonelectroleone crystal form I are achieved Reproducibility improves the solubility of the drug and its clinical application value.
Patent Information
- Application Number
- CN202411518080.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-29
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The preparation method of the non-nelinone crystal form in the prior art has problems of low yield and high cost, which leads to uncertainty in drug applications.
The crystallization of fennelone is carried out by high boiling solvents such as methanol, isopropanol, sec-butanol, tert-butanol, acetonitrile and N,N-dimethylformamide. The crystallization is performed by heating, dissolving, filtration, concentration, cooling and crystallization. In the drying step, isopropanol is preferred as a solvent to increase yield and reduce costs.
The high yield and good reproducibility of the non-nelinone crystal form I have been achieved, the solubility of the drug and the clinical application value are improved, and the production cost is reduced.
Smart Images

Figure CN119019395A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of drug synthesis, and in particular to a method for preparing finerenone crystal form I. Background Art
[0002] Mineralocorticoid receptors regulate blood pressure by regulating the effects of aldosterone on renal sodium handling. The expression of mineralocorticoid receptors in the cardiovascular system is now clear, and researchers are increasingly studying the role of mineralocorticoid receptors in regulating vascular function and affecting cardiovascular disease. Several clinical studies have shown that drugs that reduce mineralocorticoid receptor activation reduce the incidence of stroke and heart disease. Finerenone can be used as a nonsteroidal antagonist of mineralocorticoid receptors and can be used as an agent for the prevention and / or treatment of cardiovascular and renal diseases such as heart failure and diabetic nephropathy. Finerenone, chemical name (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide, is a first-in-class, nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) developed by Bayer Healthcare Pharmaceuticals in Germany. It has been shown to have renal and cardiovascular benefits for patients with CKD and T2D in the Phase III FIDELIO-DKD study. This product has been approved in the United States, the European Union and Japan for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Summary of the invention
[0003] In view of this, the technical problem to be solved by the present invention is to provide a method for preparing finerenone crystal form I with a higher yield.
[0004] To achieve the above object, the present invention provides a method for preparing finerenone crystal form I, comprising the following steps:
[0005] (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide (phenarenon) is crystallized in a solvent, filtered, and dried to obtain phenarenon crystal form I;
[0006] The solvent includes one or more of methanol, isopropanol, sec-butanol, tert-butanol, acetonitrile, N,N-dimethylformamide, and N,N-dimethylacetamide.
[0007] The solvent is preferably isopropanol.
[0008] The solvent is preferably acetonitrile.
[0009] Finerenone of the present invention has the following structural formula:
[0010] .
[0011] The finerenone crystal form I (isopropyl alcohol) has the following characteristics:
[0012] The results were obtained by using a DX2700 X-ray diffractometer under the following conditions: Cu / Kα1 line (λα1=1.54059Å), 40 kV, and 30 mA excitation. The spectrum had the following diffraction angle (2θ), interplanar spacing (d value), and intensity (%). The error of 2θ was 0.02.
[0013]
[0014]
[0015] Comparing the diffraction angle (2θ) of the above spectrum with the XRD spectrum of the crystalline form prepared by ethanol recrystallization, it can be seen that the crystalline form I of phenedrine prepared by ethanol recrystallization has an additional absorption peak at a diffraction angle of 6.65 (2θ), indicating that the crystalline form I of phenedrine prepared by the present invention is different from the crystalline form of phenedrine prepared by ethanol recrystallization.
[0016] The present invention has no particular limitation on the source of the finerenone, which can be commercially available or prepared by methods well known to those skilled in the art. Preferably, the reaction scheme is as follows:
[0017]
[0018] Finerenone has polymorphic forms, and different preparation processes result in inconsistent crystal forms.
[0019] The present invention uses alcohols such as methanol, ethanol, isopropanol, sec-butanol, tert-butanol, and high boiling point solvents such as acetonitrile, N,N-dimethylformamide, N,N-dimethylacetamide as crystallization solvents for finerenone, and more preferably uses isopropanol solvent. Compared with ethanol, under the same conditions, the solubility of finerenone is lower, the product yield is increased, and the production cost is reduced.
[0020] Preferably, the method of the present invention is to first heat and dissolve finerenone in a solvent, concentrate to a certain volume after hot filtration, cool and crystallize, filter and dry to obtain finerenone crystals.
[0021] The feed ratio of finerenone to solvent is preferably 1:(1-100) (g / mL), more preferably 1:(10-30) (g / mL), and more preferably 1:20 (g / mL).
[0022] The temperature for heating and dissolving is preferably 30 to 100°C, more preferably 60 to 80°C, and even more preferably 70 to 80°C.
[0023] The heating and dissolving time is preferably 1 to 30 hours, more preferably 2 to 8 hours.
[0024] After heating and dissolving, the insoluble matter was removed by hot filtration, and then the solvent was partially removed by concentration.
[0025] Preferably, the concentration is to concentrate to 1 / 3 to 1 / 5 of the volume, more preferably to concentrate to 1 / 4 of the volume.
[0026] The temperature of the cooling crystallization is preferably 0-50°C, more preferably 0-25°C.
[0027] The cooling and crystallization time is preferably 0.5 to 24 hours, more preferably 0.5 to 3 hours, and further preferably 2 hours.
[0028] After filtration, the filter cake is dried.
[0029] The drying temperature is preferably 40-60°C, more preferably 50°C.
[0030] The drying is preferably carried out under vacuum conditions.
[0031] Its structure was characterized by XRD powder diffraction, TGA-DSC, IR and NMR.
[0032] The finerenone crystal form obtained by crystallization in isopropanol of the present invention has peak maxima at 2θ angles of 8.5, 15.4, 19.0, 19.7, 22.9, 23.9 and 26.4 in its X-ray diffraction diagram.
[0033] The phenerenone crystal form I prepared by the present invention can be used as a pharmaceutically active ingredient for preventing or treating cardiovascular and kidney diseases such as heart failure, diabetes, nephropathy, etc.
[0034] Compared with the prior art, the present invention provides a method for preparing finerenone crystal form I, comprising the following steps: crystallizing (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide in a solvent, filtering, and drying to obtain finerenone crystal form I; the solvent comprises one or more of methanol, isopropanol, sec-butanol, tert-butanol, acetonitrile, N,N-dimethylformamide, and N,N-dimethylacetamide.
[0035] The finerenone crystal form I prepared by the above method has good solubility and can improve the clinical application value of the drug. Within the process parameter range described in the above preparation method, finerenone crystal form I was prepared in multiple batches with good reproducibility. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 is the TGA-DSC graph of finerenone crystal form I in Example 1;
[0037] Figure 2 is the XRD powder diffraction pattern of finerenone crystal form I in Example 1; the vertical axis represents the peak intensity, and the horizontal axis represents the diffraction angle (2θ);
[0038] Figure 3 is the infrared spectrum of finerenone crystal form I in Example 1;
[0039] Figure 4 is the hydrogen nuclear magnetic resonance spectrum of finerenone crystal form I in Example 1;
[0040] Figure 5 is the XRD powder diffraction pattern of finerenone crystal form I in Example 2; the vertical axis represents the peak intensity, and the horizontal axis represents the diffraction angle (2θ);
[0041] Figure 6 is the XRD powder diffraction pattern of finerenone crystal form I in comparative example 1; the vertical axis represents the peak intensity, and the horizontal axis represents the diffraction angle (2θ);
[0042] Figure 7 This is the infrared comparison of the isopropanol recrystallized sample of phenerenone and the ethanol recrystallized sample. DETAILED DESCRIPTION
[0043] In order to further illustrate the present invention, the preparation method of finerenone crystal form I provided by the present invention is described in detail below in conjunction with the examples. However, it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention, rather than limiting the claims of the invention.
[0044] All raw materials of the present invention have no particular limitation on their sources, and can be purchased from the market or prepared according to conventional methods known to those skilled in the art.
[0045] Example 1
[0046] Isopropanol (100 mL) was added to the reactor, and finerenone (5.00 g) was added under stirring. The temperature was raised to 70°C~80°C, stirred to dissolve, filtered while hot, and the filtrate was concentrated to about 1 / 4 volume under reduced pressure, stirred and cooled to 0°C~25°C, kept warm and stirred for 2 hours, filtered, and the filter cake was dried under vacuum at 50°C to obtain 4.3 g of finerenone with a yield of 86%, a purity of 99.86%, and a melting point of 235.5°C~236.3°C. The obtained samples were subjected to relevant TGA-DSC, XRD powder diffraction, infrared and 1 H-NMR study, TGA-DSC see Figure 1 , XRD powder diffraction Figure 2 , infrared Figure 3 , 1 H-NMR Figure 4 .
[0047] Example 2
[0048] Acetonitrile (100 mL) was added to the reactor, and finerenone (5.00 g) was added under stirring. The temperature was raised to 70°C~80°C, and the solution was stirred and dissolved. The solution was filtered while hot, and the filtrate was concentrated to about 1 / 4 volume under reduced pressure. The solution was stirred and cooled to 0°C~25°C, and the temperature was kept stirred for 2 hours. The filter cake was dried under vacuum at 50°C to obtain 3.2 g of finerenone with a yield of 64% and a purity of 99.83%. The melting point was 238.2°C~238.5°C. The XRD powder diffraction pattern was shown in detail. Figure 5 .
[0049] Comparative Example 1
[0050] Anhydrous ethanol (100 mL) was added to the reactor, and finerenone (5.00 g) was added under stirring. The temperature was raised to 70°C-80°C, and the solution was stirred and filtered while hot. The filtrate was concentrated to about 1 / 4 volume under reduced pressure, and the temperature was lowered to 0°C-25°C under stirring. The mixture was kept warm and stirred for 2 hours, and filtered. The filter cake was dried under vacuum at 50°C to obtain 3.6 g of finerenone, with a yield of 72% and a purity of 98%. For specific XRD powder diffraction, see Figure 6 .
[0051] Example 3
[0052] Isopropanol (6.0 L) was added to the reactor, and finerenone (300.00 g) was added under stirring. The temperature was raised to 70°C-80°C, stirred to dissolve, filtered while hot, and the filtrate was concentrated to about 1 / 4 volume under reduced pressure, stirred and cooled to 0°C-10°C, kept warm and stirred for 2 h, filtered, and the filter cake was dried under vacuum at 50°C to obtain 264.8 g of finerenone with a yield of 88.3% and a purity of 99.85%.
[0053] Example 4
[0054] The solubility of the samples before and after recrystallization with ethanol and isopropanol was tested according to the statutory method specified in the Chinese Pharmacopoeia 2020 Edition. The specific results are shown in Table 1. The solubility of the samples obtained by different methods was tested, and the specific results are shown in Table 2.
[0055] Table 1: Statistics of sample solubility obtained by recrystallization from ethanol and isopropanol
[0056]
[0057] Note: Soluble: refers to that 1g (ml) of solute can be dissolved in 10 to less than 30ml of solvent; Slightly soluble: refers to that 1g (ml) of solute can be dissolved in 30 to less than 100ml of solvent; Slightly soluble: refers to that 1g (ml) of solute can be dissolved in 100 to less than 1000ml of solvent.
[0058] Conclusion: Compared with the original ethanol preparation method, the solubility of the samples prepared by isopropanol is basically consistent with that of the samples prepared by the original method.
[0059] Table 2: Melting point statistics of different samples
[0060]
[0061] Figure 7 This is an infrared comparison of the isopropanol recrystallized sample of finerenone and the ethanol recrystallized sample. Figure 7 It can be seen that the infrared spectrum of the sample prepared by isopropanol is basically consistent with that of the sample prepared by ethanol.
[0062] The above embodiments are only used to help understand the method and core idea of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.
Claims
1. A method for preparing finerenone crystal form I, The following steps are involved: (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide is crystallized in a solvent, filtered, and dried to obtain finerenone crystal form I; The solvent is isopropanol; The X-ray diffraction pattern of the finerenone crystal form I has peak maxima at 2θ angles of 8.5, 15.4, 19.0, 19.7, 22.9, 23.9, and 26.
4.
2. The preparation method according to claim 1, It is characterized in that The following steps are involved: (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide is heated and dissolved in a solvent, filtered hot and concentrated, cooled for crystallization, filtered and dried to obtain finerenone crystals.
3. The preparation method according to claim 1 or 2, It is characterized in that The feed ratio of the (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide to the solvent is 1:1-100 (g / mL).
4. The preparation method according to claim 2, It is characterized in that The temperature of the heating and dissolving is 30-100°C.
5. The preparation method according to claim 2, It is characterized in that The heating and dissolving time is 1 to 30 hours.
6. The preparation method according to claim 2, It is characterized in that The concentration is concentrated to 1 / 3 to 1 / 5 of the volume.
7. The preparation method according to claim 2, It is characterized in that The temperature of the cooling and crystallization is 0-50°C; the time of the cooling and crystallization is 0.5-24h.
8. The preparation method according to claim 2, It is characterized in that The drying temperature is 40-60°C.
Citation Information
Patent Citations
Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
CN106795155A
Crystal form preparation and synthesis method of 1, 4-dihydro-1, 6-naphthyridine compound
CN114524812A
Fenerenone, preparation method thereof and fenerenone intermediate
CN117964619A
Process for the preparation of finerenone and intermediates thereof
IN202221027928A
Amorphous solid dispersions of finerenone
IN202241032372A
Cited By
Preparation method of fenerenone crystal form
CN119431370A
